Search research articles
Contact Us
Filters
Showing results (21-30 of 57) with videos related to
Page
of 6
Sort By:
Pharmacoeconomics
|
January 9, 2020
A French Value Set for the EQ-5D-5L
Luiz Flavio Andrade, Kristina Ludwig, Juan Manuel Ramos Goni, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 16, 2017
Quality Control Process for EQ-5D-5L Valuation Studies
Juan M Ramos-Goñi, Mark Oppe, Bernhard Slaap, et al.
Plos One
|
February 3, 2017
Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes
Pepijn Vemer, Maiwenn J Al, Mark Oppe, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
August 1, 2013
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
Matthijs M Versteegh, Arthur E Attema, Mark Oppe, et al.
Health and Quality of Life Outcomes
|
August 2, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement
Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
International Journal of Technology Assessment in Health Care
|
August 4, 2015
PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT
Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
April 21, 2021
Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, et al.
Health Economics
|
March 8, 2012
Lead time TTO: leading to better health state valuations?
Arthur E Attema, Matthijs M Versteegh, Mark Oppe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 16, 2009
Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research
Jan B Oostenbrink, Maiwenn J Al, Mark Oppe, et al.
Journal of Medical Economics
|
August 22, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement
Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 57) with videos related to
Sort By:
Page
of 6
Pharmacoeconomics
|
January 9, 2020
A French Value Set for the EQ-5D-5L
Luiz Flavio Andrade, Kristina Ludwig, Juan Manuel Ramos Goni, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 16, 2017
Quality Control Process for EQ-5D-5L Valuation Studies
Juan M Ramos-Goñi, Mark Oppe, Bernhard Slaap, et al.
Plos One
|
February 3, 2017
Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes
Pepijn Vemer, Maiwenn J Al, Mark Oppe, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
August 1, 2013
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
Matthijs M Versteegh, Arthur E Attema, Mark Oppe, et al.
Health and Quality of Life Outcomes
|
August 2, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement
Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
International Journal of Technology Assessment in Health Care
|
August 4, 2015
PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT
Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
April 21, 2021
Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, et al.
Health Economics
|
March 8, 2012
Lead time TTO: leading to better health state valuations?
Arthur E Attema, Matthijs M Versteegh, Mark Oppe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 16, 2009
Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research
Jan B Oostenbrink, Maiwenn J Al, Mark Oppe, et al.
Journal of Medical Economics
|
August 22, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement
Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Page
of 6